Defining Meaningful Tuberous sclerosis Outcomes for Research (MTOR)

Background
Tuberous sclerosis complex (TSC) is an autosomal dominant genetic condition. The gene variant shows variable expression; common manifestations include epilepsy, intellectual disability, TSC associated neuropsychiatric disorder (TAND) as well as the presence of multiple tumour types such as renal angiomyolipoma and subependymal giant cell astrocytoma (SEGA). Over the last two decades there has been a shift towards precision medicine and the development of disease modifying therapies.
The presence of a core outcome set (COS) facilitates a unified research approach using the most important and useful outcomes. A consistent approach between researchers facilitates the option for data synthesis, which is particularly beneficial in rare disease, such as TSC, where participant numbers are limited. There is currently no COS for use in tuberous sclerosis research.

Objective
The aim of this project is to develop a COS to be used in research when evaluating efficacy or effectiveness of interventions for TSC. Given the variability and multisystem involvement of TSC, as well as a ‘core set’, we aim to produce subsets for specific populations within this heterogenous patient group.

Other potentially relevant COS from COMET search:
The COS4TAND project has registered a project that is developing a core outcome set for TAND. (1) Given the complexity of this sub diagnosis as well as the registration of this project, we are excluding TAND related outcomes from our project.
Mitchell et al. has developed COS for both adults and children with epilepsy for use in routine practice.(2,3) Lux et al. have performed a consensus process around the definition and outcomes to be used in infantile spams.(4) Neither study provides core outcomes specific to TSC in the research setting.
Epilepsy is not the only manifestation of TSC and the COMET database does not hold COS for other aspects of the condition such as renal angiomyolipoma, SEGA or lymphangioleiomyomatosis.
With the emergence of disease modifying therapies, this outcome set aims to create a list of outcomes that allow for evaluation of interventions for the heterogenous TSC population. By creating subsets we can also provide specific groups of outcomes for use when evaluating efficacy or effectiveness for specific subpopulations e.g. refractory epilepsy subset.

References:
1. COMET Initiative | COS4TAND: Towards a Core Outcome (Measure) Set for TSC-Associated Neuropsychiatric Disorders (TAND). Accessed October 12, 2026. https://www.comet-initiative.org/Studies/Details/3702
2. Mitchell JW, Sossi F, Miller I, et al. Development of an International Standard Set of Outcomes and Measurement Methods for Routine Practice for Infants, Children, and Adolescents with Epilepsy: The International Consortium for Health Outcomes Measurement Consensus Recommendations. Epilepsia. 2024;65(7):1938-1961. doi:10.1111/epi.17976
3. Mitchell JW, Sossi F, Miller I, et al. Development of an International Standard Set of Outcomes and Measurement Methods for Routine Practice for Adults with Epilepsy: The International Consortium for Health Outcomes Measurement Consensus Recommendations. Epilepsia. 2024;65(7):1916-1937. doi:10.1111/epi.17971
4. Lux AL, Osborne JP. A Proposal for Case Definitions and Outcome Measures in Studies of Infantile Spasms and West Syndrome: Consensus Statement of the West Delphi Group. Epilepsia. 2004;45(11):1416-1428. doi:10.1111/j.0013-9580.2004.02404.x

Contributors

Sophie Pettler (Project lead)
Surjabha Pal
Sam Amin (Senior supervisor)

Further Study Information

Current Stage: Ongoing
Date: October 2026 - September 2029
Funding source(s): As part of PhD project at University of Bristol


Health Area

Disease Category: Neurology, Genetic disorders

Disease Name: Tuberous Sclerosis Complex

Target Population

Age Range: 0 - 100

Sex: Either

Nature of Intervention: Any

Stakeholders Involved

- Charities
- Clinical experts
- Consumers (caregivers)
- Consumers (patients)
- Pharmaceutical industry representatives
- Researchers

Study Type

- COS for clinical trials or clinical research

Method(s)

- Delphi process
- Focus group(s)
- Systematic review

These core outcomes will be designed as per the COMET handbook and ‘COS-STAD’ recommendations. Following specification of the scope of the COS, a systematic review of outcomes used in TSC research will be performed to create an initial list. The next stage includes stakeholder involvement including patients, clinicians, researchers and industry. Lastly there will be a consensus process to finalise the list of core outcomes.

Linked Studies

    No related studies


Related Links

    No related links